NasdaqHealth CarePharmaceutical PreparationsSOMERVILLE, MA

Cue Biopharma, Inc. CUE

Ask your AI

Estimated market cap $117.10M7.26M shares, shares as of Aug 12, 2026CIK 1645460

Insider trades, 12 mo

5 buys · 11 sells

$2.04M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

23.4% of shares · 11 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

IPO prospectus

Updated

Cue Biopharma, Inc.’s initial public offering: where it stands and what the registration statement says.

Updated · Proposed ticker CUE, Nasdaq Capital Market · First filed Sep 21, 2017

Read from the S-1/A filed Dec 13, 2017 · Read it on sec.gov ↗

Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.

AI summary of the prospectus. Written by AI from the parts of the prospectus listed in the filing, and checked against its text. This is information, not investment advice.

All filings of this IPO Read the S-1/A on sec.gov ↗

IPO prospectus

Cue Biopharma, Inc.’s initial public offering: where it stands and what the registration statement says.

Loading…

Latest 10-Q

Q2 2026

What changed in Cue Biopharma, Inc.'s latest quarterly report, compared with the one before.

Filed Aug 14, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Cue Biopharma, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

16 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Aug 13, 2026. Insiders have two business days to file.

Recent insider trades

Michael Vincent Meluzio VP, Prin. Accounting Officer	Aug 13 Form 4 ↗	Sale	−$93.39 3 sh @ $31.13	-45.1%
Michael Vincent Meluzio VP, Prin. Accounting Officer	Aug 13 Form 4 ↗	Sale	−$124.6K 4,106 sh @ $30.35	-45.1%
Michael Vincent Meluzio VP, Prin. Accounting Officer	Aug 13 Form 4 ↗	Sale	−$44.6K 1,519 sh @ $29.37	-45.1%
Sumita Ray Chief Legal Compliance Officer	Aug 13 Form 4 ↗	Sale	−$125 4 sh @ $31.13	-45.1%
Sumita Ray Chief Legal Compliance Officer	Aug 13 Form 4 ↗	Sale	−$195.5K 6,442 sh @ $30.35	-45.1%

All CUE insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

1.70M shares

32 funds report CUE. Values checked against market prices.

Funds own 23% of shares (Q2 2026)

48 funds hold the stock.

Q3 2026: 23% · 5,560 of ~8,900 funds reported so far

Q1 2026<0.1%
Q2 202623%
Q3 2026 (so far)23%

Q3 2026. 8 new, 11 added to, 6 trimmed, 25 exited since Q2 2026.

Top 13F holders
#
1	Bleichroeder LP 13F ↗	366,152	$9.5M	-1.2%
2	Vanguard Capital Management LLC 13F ↗	309,948	$8.0M	+91.7%
3	Vivo Capital, LLC 13F ↗	280,057	$7.2M	New
4	Morgan Stanley 13F ↗	203,957	$5.3M	+30160.7%
5	UBS Group AG 13F ↗	111,496	$2.9M	+317.6%
6	Nantahala Capital Management, LLC 13F ↗	96,049	$2.5M	New
7	Geode Capital Management, LLC 13F ↗	68,911	$1.8M	+44.1%
8	BlackRock, Inc. 13F ↗	55,369	$1.4M	-4.2%
9	Vanguard Fiduciary Trust Co 13F ↗	41,337	$1.1M	+68.9%
10	Jane Street Group, LLC 13F ↗	36,071	$933.2K	New

Download CSV Every fund that holds CUE, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Cue Biopharma, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Cue Biopharma, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q1 2026	2	—	57	$391
Q2 2026	49	+47	1.64M	$51.8M
Q3 2026	32	-17	1.70M	$44.0M

Each point is a quarter-end, from Q1 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (22978P205). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-30 on Apr 24, 2026): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes4 in 12 mo 8-K events1 in 90 days Patents8 patents granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 6 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials0 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Cue Biopharma, Inc.
Address: 100 CHESTNUT STREET, SUITE 300, SOMERVILLE, MA 02143
Phone: 617-949-2680
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: CUE (Nasdaq)
Former names: Imagen Biopharma, Inc. (until 2015)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$16.12−$1.38 (−7.89%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $16.08 · High $21.45Nov 13, 2026

Aug 13, 2026Low $16.08 · High $37.84Nov 13, 2026

Nov 13, 2025Low $5.31 · High $37.84Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. The stock split 1-for-30 on Apr 24, 2026; earlier prices are shown divided by the split ratio. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.